European Commission Approves Sandoz Biosimilar Erelzi to Treat Various Inflammatory Diseases
The European Commission recently approved Erelzi, a biosimilar etanercept drug manufactured by the Sandoz division of Switzerland’s Novartis, for all therapeutic indications of its reference medicine Enbrel (etanercept), including ankylosing spondylitis. The June 27 announcement followed an extensive analytical, preclinical and clinical program focused on Erelzi, formerly known…